Shares of ChemoCentryx Inc (NASDAQ:CCXI) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.86 and last traded at $6.29, with a volume of 57400 shares traded. The stock had previously closed at $6.47.
Several analysts have issued reports on the company. Cowen reaffirmed a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Finally, ValuEngine downgraded ChemoCentryx from a “hold” rating to a “sell” rating in a research report on Saturday, October 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.25.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. sell-side analysts predict that ChemoCentryx Inc will post -0.67 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/06/chemocentryx-ccxi-hits-new-52-week-low-at-5-86.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
What are top analysts saying about ChemoCentryx Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ChemoCentryx Inc and related companies.